Cgtcdmo

About Cgtcdmo

This company offers CDMO (Contract Development and Manufacturing Organization) services for gene and cell therapy drug companies. They provide end-to-end support, including process development, quality control, production, and regulatory registration, to accelerate the clinical development of cell and gene therapy drugs.

```xml <problem> Gene and cell therapy companies face significant challenges in scaling up production, ensuring quality control, and navigating complex regulatory requirements, which can delay clinical development and market entry. Many companies lack in-house expertise and infrastructure for GMP-compliant manufacturing of plasmids, viral vectors, and cell therapies. </problem> <solution> This company provides comprehensive CDMO services, offering gene and cell therapy developers an integrated platform to accelerate their programs from research to commercialization. With over 8,000 square meters of GMP-compliant facilities, the company supports the entire CGT product lifecycle, including process development and optimization, analytical method development and validation, GMP manufacturing, quality control testing, and regulatory consulting. Their platform is designed to meet FDA, EMA, and NMPA standards, ensuring product quality and compliance throughout the development process. </solution> <features> - Dedicated GMP manufacturing suites for plasmids, viral vectors (LV, RV, AAV), and cell therapies (T cells, NK cells, MSCs, iPSCs) - Process development and optimization using QbD principles - Analytical method development, validation, and release testing - Comprehensive quality control services, including sterility, mycoplasma, endotoxin, and vector RCL/RCA testing - Fill and finish services with support for various container types and fill volumes - Regulatory consulting and support for IND and NDA submissions - GMP consulting services, including quality management system setup, audits, and gap analysis - Facility and equipment validation services - Cleanroom laundry services </features> <target_audience> The primary target audience includes gene and cell therapy companies, biotech firms, and academic institutions seeking outsourced development and manufacturing services to advance their therapeutic candidates. </target_audience> ```

What does Cgtcdmo do?

This company offers CDMO (Contract Development and Manufacturing Organization) services for gene and cell therapy drug companies. They provide end-to-end support, including process development, quality control, production, and regulatory registration, to accelerate the clinical development of cell and gene therapy drugs.

When was Cgtcdmo founded?

Cgtcdmo was founded in 2022.

Founded
2022
0

Cgtcdmo

10
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

This company offers CDMO (Contract Development and Manufacturing Organization) services for gene and cell therapy drug companies. They provide end-to-end support, including process development, quality control, production, and regulatory registration, to accelerate the clinical development of cell and gene therapy drugs.

cgtcdmo.com
Founded 2022

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Gene and cell therapy companies face significant challenges in scaling up production, ensuring quality control, and navigating complex regulatory requirements, which can delay clinical development and market entry. Many companies lack in-house expertise and infrastructure for GMP-compliant manufacturing of plasmids, viral vectors, and cell therapies.

Solution

This company provides comprehensive CDMO services, offering gene and cell therapy developers an integrated platform to accelerate their programs from research to commercialization. With over 8,000 square meters of GMP-compliant facilities, the company supports the entire CGT product lifecycle, including process development and optimization, analytical method development and validation, GMP manufacturing, quality control testing, and regulatory consulting. Their platform is designed to meet FDA, EMA, and NMPA standards, ensuring product quality and compliance throughout the development process.

Features

Dedicated GMP manufacturing suites for plasmids, viral vectors (LV, RV, AAV), and cell therapies (T cells, NK cells, MSCs, iPSCs)

Process development and optimization using QbD principles

Analytical method development, validation, and release testing

Comprehensive quality control services, including sterility, mycoplasma, endotoxin, and vector RCL/RCA testing

Fill and finish services with support for various container types and fill volumes

Regulatory consulting and support for IND and NDA submissions

GMP consulting services, including quality management system setup, audits, and gap analysis

Facility and equipment validation services

Cleanroom laundry services

Target Audience

The primary target audience includes gene and cell therapy companies, biotech firms, and academic institutions seeking outsourced development and manufacturing services to advance their therapeutic candidates.

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.